Workflow
Mustang Bio(MBIO)
icon
Search documents
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
ZACKS· 2024-06-18 15:26
Core Insights - Mustang Bio's MB-106 therapy demonstrated a 90% overall response rate (ORR) in patients with Waldenstrom macroglobulinemia (WM), including three complete responses (CR) and six partial responses [1][10] - The therapy is being developed for relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL), with plans to expand into autoimmune indications [3][12] - Mustang Bio's stock has underperformed, losing 44.4% year to date compared to the industry's 7.1% decline [2] Efficacy and Safety - MB-106 showed a favorable safety and efficacy profile in a cohort of heavily pre-treated WM patients, all of whom were refractory to BTK inhibitors [5][12] - The therapy's results improved from a previous study where the ORR was 83% with two CRs [6][10] - If approved, MB-106 would be the first FDA-approved therapy for WM patients in the third-line setting [7] Market Context - Currently, there are no FDA-approved CAR T treatments for WM, indicating a significant unmet need that MB-106 could address [12] - The FDA granted orphan drug designation to MB-106 for the WM indication in 2022, highlighting its potential in the market [12] - Competing therapies in the WM space include Imbruvica and Brukinsa, both of which are BTK inhibitors [13][14]
Why Is Mustang Bio (MBIO) Stock Up 58% Today?
investorplace.com· 2024-05-22 12:04
Core Viewpoint - Mustang Bio (NASDAQ:MBIO) is experiencing a significant increase in stock trading volume, with over 13.9 million shares traded, far exceeding its average of 345,000 shares, amidst a delisting notice from Nasdaq [1][2]. Group 1: Stock Performance - MBIO stock has surged by 58.4% as of Wednesday morning, although it has declined by 76.5% year-to-date as of the previous market close [4]. - The company has a float of 9.36 million shares, indicating a relatively low number of shares available for trading [1]. Group 2: Delisting Notice - Mustang Bio received a delisting notice from Nasdaq due to its shares trading below the minimum bid price of $1 for an extended period [2][3]. - The company has until November 12, 2024, to regain compliance with Nasdaq's listing standards by maintaining a share price above $1 for 10 consecutive trading days [2][3]. - If compliance is not achieved, Mustang Bio may qualify for an additional 180-day extension to adjust its share price [4].
Mustang Bio(MBIO) - 2024 Q1 - Quarterly Report
2024-05-15 20:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38191 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | ...
Mustang Bio(MBIO) - 2023 Q4 - Annual Results
2024-03-11 20:30
Financial Performance - As of December 31, 2023, Mustang's cash and cash equivalents totaled $7.0 million, a decrease of $69.7 million from $76.7 million as of December 31, 2022[6]. - Net loss attributable to common stockholders was $51.6 million, or $6.00 per share, for the year ended December 31, 2023, compared to a net loss of $77.5 million, or $10.09 per share, for 2022[6]. - Total assets decreased from $92,422,000 in 2022 to $17,742,000 in 2023, a decline of approximately 81.8%[16]. - Total liabilities reduced significantly from $46,149,000 in 2022 to $17,619,000 in 2023, a decrease of about 61.8%[16]. - Operating expenses for 2023 were $49,260,000, down from $76,159,000 in 2022, representing a reduction of approximately 35.4%[18]. - Net loss for 2023 was $51,602,000 compared to a net loss of $77,525,000 in 2022, indicating an improvement of approximately 33.4%[18]. - Net loss per common share improved from $10.09 in 2022 to $6.00 in 2023[18]. - Cash and cash equivalents decreased from $75,656,000 in 2022 to $6,234,000 in 2023, a decline of approximately 91.8%[16]. - Total stockholders' equity fell from $46,273,000 in 2022 to $123,000 in 2023, a decrease of about 99.7%[16]. - Interest expense increased from $3,359,000 in 2022 to $4,109,000 in 2023, an increase of approximately 22.3%[18]. Research and Development - Research and development expenses for the year ended December 31, 2023, were $40.5 million, down from $62.5 million in 2022[6]. - Research and development expenses decreased from $62,475,000 in 2022 to $40,513,000 in 2023, a decline of about 35.2%[18]. - Mustang reported a 100% overall response rate in patients treated with MB-106 (n=9) for follicular lymphoma (FL) and Waldenstrom macroglobulinemia (WM) in a recent clinical trial[8]. - The FDA granted Orphan Drug Designation to MB-106 for the treatment of WM, with pivotal Phase 2 patient treatment expected in 2024[8]. - Mustang plans to initiate a Phase 1 multicenter clinical trial for MB-109, a combination therapy for recurrent glioblastoma, in 2024[9]. - Mustang aims to request Regenerative Medicine Advanced Therapy (RMAT) designation for indolent lymphoma from the FDA in the first half of 2024[2]. - The company anticipates the publication of proof-of-concept research for its in vivo CAR-T technology platform in 2024[10]. - In 2024, the first patients are expected to be treated in new trials for X-Linked Severe Combined Immunodeficiency (XSCID) using MB-117 and MB-217[11]. Capital Raising - Mustang completed a registered direct offering in October 2023, raising approximately $4.4 million in gross proceeds[6].
Mustang Bio(MBIO) - 2023 Q4 - Annual Report
2024-03-11 20:02
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File No. 001-38191 MUSTANG BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3828760 (State or Other Jurisdiction ...
Mustang Bio(MBIO) - 2023 Q3 - Quarterly Report
2023-11-14 21:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38191 MUSTANG BIO, INC. (Exact name of registrant as specified in its charter) Delaware 47-3828760 (State or other ju ...
Mustang Bio(MBIO) - 2023 Q2 - Quarterly Report
2023-08-14 20:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38191 MUSTANG BIO, INC. (Exact name of registrant as specified in its charter) Delaware 47-3828760 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 377 Plantation Street For the quarterly period ended June 30, ...
Mustang Bio(MBIO) - 2023 Q1 - Quarterly Report
2023-05-12 20:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38191 MUSTANG BIO, INC. (Exact name of registrant as specified in its charter) Delaware 47-3828760 (State or other jurisd ...
Mustang Bio(MBIO) - 2022 Q4 - Annual Report
2023-03-30 01:35
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File No. 001-38191 MUSTANG BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3828760 (State or Other Jurisdiction ...
Mustang Bio (MBIO) Investor Presentation - Slideshow
2023-01-27 23:52
MB-207 for previously transplanted XSCID (IL2RG) MB-101 CAR-T for GBM (IL13Rα2) Combination CAR-T + oncolytic virus (OV) Expect MB-109 Mustang IND filing 2023 UAB MB-108 Phase 1 ongoing* | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|----------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----- ...